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Background: Systematic representation of information related to genetic and non-genetic variations is required to
allow large scale studies, data mining and data integration, and to make it possible to reveal novel relationships
between genotype and phenotype. Although lots of variation data is available it is often difficult to use due to lack
of systematics.
Results: A novel ontology, Variation Ontology (VariO http://variationontology.org), was developed for annotation of
effects, consequences and mechanisms of variations. In this article instructions are provided on how VariO
annotations are made. The major levels for description are the three molecules, namely DNA, RNA and protein.
They are further divided to four major sublevels: variation type, function, structure, and property, and further up to
eight sublevels. VariO annotation summarizes existing knowledge about a variation and its effects and formalizes it
so that computational analyses are efficient. The annotations should be made on as many levels as possible. VariO
annotations are made in reference to normal states, which vary for each data item including e.g. reference
sequences, wild type properties, and activities.
Conclusions: Detailed instructions together with examples are provided to indicate how VariO can be used for
annotation of variations and their effects. A dedicated tool has been developed for annotation and will be further
developed to cover also evidence for the annotations. VariO is suitable for annotation of data in many types of
databases. As several different kinds of databases are in a process of adapting VariO annotations it is important to
have guidelines to guarantee consistent annotation.
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Variations have different effects and mechanisms. To
capture and describe the character of the variations at
DNA, RNA and protein level, the Variation Ontology
(VariO) was developed [1]. VariO annotations allow sys-
tematic descriptions which can be used e.g. for searches
of complex queries also simultaneously from several da-
tabases. Systematic descriptions have several benefits es-
pecially for computational searches and analyses and for
software development.
Variation information has been collected to various da-
tabases. Locus specific databases (LSDBs) are for individ-
ual genes or diseases and usually curated by experts in
the genes and diseases. There are currently thousands of
LSDBs available, mainly on the LOVD database manage-
ment system [2]. Central databases like SwissProt [3]
and ClinVar [4] contain information on large numbersCorrespondence: mauno.vihinen@med.lu.se
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reproduction in any medium, provided the orof genes and/or proteins and variations in them. Additional
types of variation databases include national or ethnic da-
tabases such as ETHNOS [5], chromosomal variation data-
bases such as The Database of Genomic Variants archive
(DGVa) [6], variation frequency databases including FIND-
base [7], and databases dedicated on certain types of varia-
tions or for an effect or mechanism, such as ProTherm,
a database for protein stability affecting variations [8].
Benchmark databases, such as VariBench [9], are dedi-
cated for providing gold standard datasets for method de-
velopers and assessors. All these databases would benefit
from systematic descriptions. Human Genome Variation
Society (HGVS) nomenclature is widely used for naming
variations [10], however additional systematics would be
needed. HGVS and Human Variome Project (HVP) have
released a number of recommendations [11], also for in-
creased systematics, including recommendation to use
VariO annotations [12]. The recent recommendations for
LSDB establishment and curation emphasize the import-
ance of systematics [13,14]. The goal of the GEN2PHENThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Figure 1 General structure of VariO. The ontology is designed for
annotation of effects, consequences and mechanisms of variations
at the three molecular levels, DNA, RNA and protein. Each of these
has further terms on four major sublevels: variation type, function,
structure and property. Attributes are used to modify terms at
structure or property levels to further define the terms.
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http://www.jbiomedsem.com/content/5/1/9project was to develop tools, data models and solutions
for this domain [15].
The HGVS variation nomenclature is a systematic
naming convention that is in use in some journals and
numerous databases. It provides guidelines and naming for
almost all variation types based on reference sequences.
The Mutalyzer tool can generate the names automatically
and performs a number of consistency checks [16].
VariO is intended for the description of what is chan-
ged in the variant in comparison to the normal or wild
type. Thus, it does not describe the properties of the
wild type. The annotations are made in comparison to a
reference, which varies depending on the annotated
property including e.g. reference sequences, reference
states such as wild type enzyme activity and normal kin-
etic properties. The application area of VariO is in
describing effects, consequences and mechanisms in di-
verse data sources. These include all the different types
of variation databases mentioned above. In addition,
it can benefit variation naming services [16], LSDB man-
agement systems [2], data integrators, journals etc. As
VariO has been described previously [1], the goal of this
annotator guide is to explain how annotations are made
and used.
VariO design principles
VariO terms have three biological molecules, DNA,
RNA and protein, as the starting point. All these have
four major sublevels: variation type, function, structure
and properties with more detailed sublevels. There are
altogether 8 levels of terms. The terms have a clear hier-
archy and the organization of terms for DNA, RNA and
protein has a similar and coherent layout whenever ap-
propriate. The terms for the three molecular levels are
consistent and related terms are used for related features
at different levels. Suggestions for additional terms and
updates can be sent to the ontology developers.
For visualization of terms, their definitions, relation-
ships and paths, the AmiVariO browser is available at
the VariO website. Figure 1 indicates how the levels are
organized. When possible, variations are explained at
DNA, RNA and protein levels. Each of these has sub-
levels, out of which structure and property levels can be
further modified with attribute terms. The hierarchy of
the terms has been designed to allow for a versatile and
flexible annotation.
VariO is intended for the description of all kinds of
variations and situations. In Figure 2 the distinction be-
tween terms of genetic and non-genetic origin is shown.
Terms with genetic origin describe changes either in
DNA or inherited from it to RNA and protein levels.
The non-genetic terms, called variations emerging at the
RNA or protein level, are for either biological or artificial
modifications that originate at the RNA or protein level.For example, RNA editing modifies a synthetized RNA
chain and the variations are not coded in DNA.
To keep the ontology compact, modifier attributes
form the fourth major level. These terms are used to
modify the terms at the other levels. For example, quan-
tity terms are used to modify other terms when the ef-
fect is increased, decreased or is missing the quantity of
the parameter, or when it is not changed. Instead of hav-
ing separate terms for describing increase or decrease of
a feature, existing terms can be modified with attribute
terms. This way the number of terms could be reduced
considerably.
VariO terms should be combined with other systemat-
ics and ontologies. Evidence Ontology (ECO) terms [17]
are used to describe the methods with which the annota-
tions were obtained.
VariO aims at describing any effect, consequence and
mechanism, at any organism. The variations can be of
genetic or non-genetic origin. The size of the variation
does not matter, anything ranging from nucleotide or
amino acid changes to chromosome or genome duplica-
tions can be annotated. However, the annotations are
position based, even if the position means e.g. an entire
chromosome.
Example of VariO annotation
This example highlights a number of aspects of annota-
tions with VariO. The annotations are used to explain
Figure 2 Variation types for terms with genetic or non-genetic origin. The variation type annotations are made based on whether the
variation is of genetic or non-genetic origin. Genetic terms are used for alterations originating from the genetic material of the organism (DNA or
RNA, depending on the organism), while terms with non-genetic origin are either artificial or originated from the processing of RNA or protein
molecules without change in the corresponding DNA.
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systematic way. It may be tiring for a human reader to
see the same concept every time it is mentioned, how-
ever, for computational analyses it is a blessing and facili-
tates fast searches. For the annotation we are developing a
tool called VariOtator [18].
Here is a real life example of variation in the AIRE
gene leading to the autoimmune polyendocrine syn-
drome type 1 (APS-1) also called for APECED disease
(autoimmune polyendocytopathy-candidiasis-ectodermal
dystrophy), an autoimmune polyendocrine syndrome.
AIRE, autoimmune regulator, is a transcriptional regulator
of tissue-specific antigens. Variations affect the regulation,
leading to the production of self-reactive antigens. The
T >C variation leading to a L to P substitution in the homo-
geneous staining region (HSR) domain is disease causing
[19] (AIREbase [20,21] entry A0087). The functional and
other aspects of APECED-causing variations were further
studied in [22].
The genomic variant g.4789 T > C in the IDbase refer-
ence sequence D0003 (http://structure. bmc.lu.se/cgi-
bin/fetch_idrefseq.cgi?ac = D0003&format = embl, cross-
reference to EMBL:AB006682) is annotated as follows.
VariO:0128 variation affecting DNA
VariO:0129 DNA variation type
VariO:0322 DNA variation classification
VariO:0135 DNA chain variation
VariO:0136 DNA substitution
VariO:0313 transition
VariO:0314 pyrimidine transitionThe variation is of genetic origin
VariO:0128 variation affecting DNA
VariO:0129 DNA variation type
VariO:0127 DNA variation origin
VariO:0130 DNA variation of genetic origin
There is a pyrimidine transition of genetic origin.
The effect to RNA sequence (IDbase reference sequence
C:0003 http://structure.bmc.lu.se/cgi-bin/fetch_idrefseq.
cgi?ac = C0003& cross referenced to EMBL; AB006682)
is, similar at DNA level, a pyrimidine transition, which
causes a missense variation.
VariO:0297 variation affecting RNA
VariO:0306 RNA variation type





On the protein level the reference sequence is UniProt
entry O43918. A variation has different annotations at
different levels. In this example, the amino acid substitu-
tion at protein level is annotated as DNA substitution
on DNA level, and on RNA level as RNA nucleotide
substitution of type missense variation.
The annotations are richer on protein level as the ef-
fects of the variation affect protein function, structure
and properties.
Vihinen Journal of Biomedical Semantics 2014, 5:9 Page 4 of 8
http://www.jbiomedsem.com/content/5/1/9VariO:0002 variation affecting protein
VariO:0012 protein variation type
VariO:0325 protein variation classification
VariO:0021 amino acid substitution
The protein variation is due to change at the DNA level.
VariO:0002 variation affecting protein
VariO:0323 protein variation origin
VariO:0013 protein variation of genetic origin
This variant was shown to prevent transactivation, a
protein information transfer function.
VariO:0002 variation affecting protein
VariO:0003 variation affecting protein function
VariO:0011 effect on protein information transfer
The annotations for the structure include predicted ef-
fects on the protein secondary and tertiary structure.
Introduction of a proline in the middle of α-helix affects
the protein fold leading to conformational change.
VariO:0002 variation affecting protein
VariO:0060 variation affecting protein structure
VariO:0064 effect on protein 3D structure
VariO:0070 effect on protein tertiary structure
VariO:0079 effect on protein secondary structural
element
VariO:0080 effect on protein helix
VariO:0082 effect on right handed protein helix
VariO:0085 effect on alpha helix
VariO:0002 variation affecting protein
VariO:0060 variation affecting protein structure
VariO:0064 effect on protein 3D structure
VariO:0070 effect on protein tertiary structure
VariO:0073 effect on protein fold
VariO:0074 protein conformational change
Properties are used for annotating various characteris-
tics. As many properties should be annotated as data is
available. The variation is disease-causing, which is indi-
cated by the pathogenicity association attribute. In the
case of attributes, only the relevant attribute, not path to
it is given. Attributes can be used to modify structure
and property terms.
VariO:0002 variation affecting protein
VariO:0032 variation affecting protein property
VariO:0047 association of protein variation to
pathogenicity; VariO:0294 disease causingThe variant affects transactivation inactivating the pro-
tein function. The property term (effect on protein activ-
ity) is again modified by the attribute (missing).
VariO:0002 variation affecting protein
VariO:0032 variation affecting protein property
VariO:0053 effect on protein activity; VariO:292 missing
Effects to protein interaction can be described in detail.
Interaction attribute terms were derived from the Protein
Interaction ontology [23] but modified for the purpose of
VariO.
VariO:0002 variation affecting protein
VariO:0032 variation affecting protein property
VariO:0058 effect on protein interaction; VariO:0292
missing
The variant prevents AIRE homomultimerization, which
is required for the transactivation activity, and is essential
for the interaction with nuclear dots and cytoplasmic fila-
ments. This can be further described by the attributes as







and the interaction with nuclear dots and cytoplasmic






Even more detailed descriptions would be possible with
VariO, however, in this case as details are missing, the an-
notations remain somewhat shallow. For instance, inter-
action physical forces cannot therefore be annotated.
The variant alters the subcellular localization of the pro-
tein. Terms for the actual change to the compartment tar-
geting are not provided as they have not been systematized.
VariO:0002 variation affecting protein
VariO:0032 variation affecting protein property
VariO:0033 effect on protein subcellular localization
This example highlights how the experimental and pre-
dicted results can be explained at multiple levels. Note that
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the property terms. Above, attributes are used as simple
modifiers of quantity for protein activity and for disease
causality, but these modifiers allow also more elabor-
ate annotations as for interactions. The VariO annota-
tion is modular and therefore any number of terms can
be used, whatever is needed to capture the type and
effects of a variant. More examples are available at http://
variationontology.org/examples.shtml.
How to get started
When annotating a variant one should combine all the
existing information about the variant and its effects.
The steps from the variation identification to a func-
tional annotation are depicted in Figure 3. In case of
contradictory results try to obtain consensus. Databases
should not reflect personal opinions, therefore the anno-
tations have to be according to the approved standards
in the field. Once the data is available all relevant aspects
should be described. This may require annotations at
several sublevels, for example variation types can be fur-
ther defined at structural level.
Once the data is available the annotation process is
relatively straightforward. The annotation tool, VariOtator,Figure 3 Flowchart for annotation with VariO. All existing
information for the variation should be available when starting
annotation. Reference sequence is needed to indicate the position
of the variation. With this information can be generated the
variation type annotation. The effects on function, structure and
property are annotated based on the obtained information. The
methods used for obtaining the results are indicated by Evidence
Codes terms. Literature and database references are used to indicate
the origin of the annotated data. It is essential that the database
using VariO annotations provides information about all relevant
reference states such as reference sequence and wild type
protein properties.can be used for generating annotations. In the future, we
will provide a full annotation tool covering also evidence.
While reading the literature find which methods have
been used to obtain the results as they are needed for
Evidence Code annotation. For ECO annotations, the
methods used for obtaining the results have to be taken
from the literature. Literature and database references de-
scribing the variant should be provided in the database.
VariO annotation
Terms at major sublevels
There are four major sublevels. Variation type is to explain
the type of variation. These annotations can be generated
from systematic HGVS names [9]. The annotation terms
do not provide the actual sequence variation information,
the change(s) at nucleotide or amino acid level, since
HGVS names are for their systematic description. Instead
they provide genetic terms for the type of the variation.
This is often useful for human users as the HGVS names
can be quite complex and one needs to be familiar with
the naming conventions to be able to decipher them
correctly.
Function terms indicate the biological function affected
by the variation. The function is annotated on the level(s)
where affected. So, effects on protein function are only de-
scribed at protein level. However, if the effect is e.g. on
RNA level then annotation is made on that level.
Structure annotations allow for an elaborate descrip-
tion of the effects to the DNA, RNA or protein struc-
ture. Due to the characteristics of the structures at the
three levels the terms vary (Figure 4). The most detailed
annotations can be made for protein changes. These
terms can be modified with attributes, when necessary/if
desired.
Property terms have great differences between the
molecular levels. Some terms are common at two or
three levels including sequence conservation, association
of the variation to pathogenicity, and interaction. Effects
to abundance, degradation and stability are shared by
RNA and protein levels. In addition, there are protein
specific terms.
Full path for terms
The VariO annotations should be presented as full paths
from the branch to the root as there is thereby more in-
formation and disambiguation can be avoided. Annota-
tions consist at least of the identifier of the term, e.g.
VariO:0022 which is composed of two parts, VariO: in
the beginning indicates what ontology is used and then
the four digit number is for the individual term. Usually
also the name of the term is added, in this example
“amino acid indel”. All terms in VariO have definitions
as well as relationships to other terms up and down in
the hierarchy.
Figure 4 Organization of major structure terms at different levels. Some sublevels are indicated.
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butes for conservation, pathogenicity association, and
quantity change. As there is just one single sublevel for
these terms they are used without the path. Since there
are several sublevels for interaction attributes they have
to be provided in full.
Provide all necessary annotations
Annotations are most useful when they are rich and de-
tailed. This is a true strength of VariO which facilitates
very detailed descriptions and equally detailed searches
for certain kinds of cases.
The more data there are the more annotations can be
made. The VariO concepts are balanced between prac-
tical application and existence of details. It would be pos-
sible to have even more detailed terms, however, cases in
which they could be used might be very limited. The level
of detail has been adjusted so that all variants and effects
can be explained to a certain extent. The ontology will
be updated in the future and new terms can be added
e.g. when new technologies are introduced and more
details are provided.
Reference states
VariO describes the consequences and mechanisms in re-
lation to a reference state. In the case of sequences, the
recommended references are Locus Reference Genomic
(LRG) [24] entries, when available. In the case of bio-
logical functions the reference is the property of the wild
type molecule. These references should be available in the
databases and explained in detail.
Use attributes as modifiers
Terms at the structure and property levels can be modi-
fied by attributes. Note that attributes are not used to
specify variation type and function terms. Attributes have
four major levels. Conservation attributes explain what
kind of change has been introduced (conserved, covariantor nonconserved). Interaction terms describe effects to
interactions. Pathogenicity association clarifies the rela-
tionship of the variation to pathogenicity, or not. Quantity
change attributes define the direction and extent of the
change and contain the terms VariO:0290 decreased,
VariO:0291 increased, VariO:0292 missing, and VariO:0140
not changed. For the use of interaction annotations see the
example above.
Evidence codes
The annotations should be accompanied by terms from
another ontology, Evidence Codes. These ECO terms de-
scribe the (experimental) method used to obtain the an-
notated feature. This will allow users to evaluate the
quality of data items. The term should be used at the
level where the description is applicable. ECO terms are
used without the full path of the terms.
To the example above some ECO terms can be added
as follows. The variant protein is inactive. This was veri-
fied by two-hybrid enzyme assay with luciferase as re-
porter. To the annotation is added ECO:0000049 reporter
gene assay evidence. The variant prevents interactions
required for the functional protein complex forma-
tion. This was revealed with gel filtration fractionation.
The term to be included is in this case ECO:0000156 pro-
tein separation evidence. The variant has also effect on
protein localization, which is annotated as ECO:0000007
immunofluorescence evidence. These specification terms
are linked to the relevant VariO annotations.
Annotation for variants of genetic and non-genetic origin
The variation may have originated on the level they are de-
scribed or be inherited from changes in DNA. Variants that
can be derived from changes on DNA are annotated with
variation types of genetic origin. The terms for VariO:0146
DNA variation of non-genetic origin, VariO:0333 variation
emerging at RNA level, and VariO:0024 variation emerging
at protein level describe changes not originating from DNA
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as well as edited RNA (Figure 2). These include also artifi-
cial variations on all three molecular levels, because VariO
is intended to allow annotation of variations e.g. originat-
ing from protein engineering.
Combine different systematics for even richer annotations
VariO is a specific ontology with a well-defined applica-
tion area. It could and should be used together with
other systematic descriptions related to variations. These
include, systematic gene names provided by the HUGO
Gene Nomenclature Committee (HGNC) [25], the HGVS
variation nomenclature [9], reference sequences, prefera-
bly LRGs [24]. For the description of clinical features the
Human Phenotype Ontology (HPO) [26] and Elements of
Morphology [27] can be used. Evidence Codes ontology
annotations should be added to further clarify the terms
by indicating the method used to obtain the results as de-
scribed above.
Minimum annotation
As VariO is position specific the minimum annotation
would include the details at DNA, RNA and protein
level, when changes on all three levels appear. However,
it is highly recommended to include additional informa-
tion at other levels, although already systematic variation
type descriptions are useful.
Include information sources
The annotations need to be supplemented with informa-
tion about the reference states as well as references to the
sources of information such as literature, database or pre-
diction. Database and literature references should be
linked to the original sources when annotating databases.
Version number
Databases using VariO annotations, and other ontologies,
should state which version of the ontology has been uti-
lized. As ontologies are under constant improvement it is
important to indicate according to which set of terms the
annotations have been made. This information applies to
the entire database and thus needs to be provided just once.
Annotation tool
We are developing dedicated software for providing an-
notations. VariOtator is available at [17] and currently
generates variation type annotations based on variation
descriptions based on HGVS names for variations as
well as structure, function and property annotations. In
the future, the tool will allow the Evidence Code annota-
tions to be incorporated.Competing interests
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